Torrent Pharmaceuticals has announced the launch of its semaglutide brands Sembolic and Semalix in India in both oral and injectable formulations.
The company has become the first in India to introduce a generic oral semaglutide, expanding treatment options for patients suffering from diabetes and obesity.
The injectable formulation has also been launched with a starting price of ₹3,999 per month, aiming to make advanced metabolic disorder therapies more accessible to patients across the country.
The introduction of Sembolic and Semalix represents a strategic move by Torrent Pharma to expand its diabetes care portfolio.
Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices.”
He further added, “We are proud to be the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients.”
The launch comes at a time when the prevalence of metabolic conditions such as diabetes and obesity continues to rise in India. Increasing lifestyle changes, urbanisation and dietary habits have contributed to a growing patient population requiring long-term medical management.
By expanding treatment options in the GLP-1 segment, Torrent Pharma aims to make advanced therapies more accessible and affordable for patients managing complex metabolic conditions.
GLP-1 receptor agonists are a class of prescription medicines widely used to treat type-2 diabetes and obesity. These medications work by mimicking the natural hormone GLP-1, which helps regulate blood sugar levels and appetite.
They improve insulin secretion, reduce glucagon levels and help control food intake. Clinical studies have also shown that GLP-1 therapies can lower haemoglobin A1c levels, promote weight loss and reduce the risk of cardiovascular complications in patients.
On March 23, 2026, Torrent Pharma share price opened at ₹4,270.30, touching the day’s low at ₹4,173.60, as of 11:15 AM on the NSE.
Also Read: Zydus and Torrent Pharma Partner to Co-Market Semaglutide Injection in India!
The launch of Sembolic and Semalix highlights Torrent Pharma’s efforts to strengthen its presence in the metabolic disorder treatment market. By offering semaglutide in both oral and injectable forms, the company aims to expand access to modern diabetes therapies while supporting healthcare professionals in managing complex patient needs.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 23, 2026, 11:24 AM IST
Nikitha Devi
Nikitha is a content creator with 7+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
